2024-2029 Belgium Therapeutic Drug Monitoring (TDM) Market Assessment for 28 Assays--2024 Supplier Shares and 2024-2029 Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

October 2024 | | ID: 2776DF8E9C6BEN
Venture Planning Group

Abstracts

This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source.The report is available by section, and can be customized to specific information needs and budget.This new report from LeadingMarketResearch.com provides a comprehensive analysis of the therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by market segment for the following assays:Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin, and Warfarin.During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.This report is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.

Contents

Introduction
Market and Technology Overview
A. Major Therapeutic Drug Monitoring Tests

1. OVERVIEW

2. AMIKACIN

3. APIXABAN

4. ARGATROBAN

5. BETRIXABAN

6. CARBAMAZEPINE

7. CYCLOSPORIN

8. DABIGATRAN

9. DIGOXIN

10. EDOXABAN

11. EVEROLIMUS

12. FLUINDIONE

13. GENTAMICIN

14. LEVETIRACETAM

15. LITHIUM

16. METHOTREXATE

17. NAPA/PROCAINAMIDE

18. PHENOBARBITAL

19. PHENYTOIN

20. QUINIDINE

21. RIVAROXABAN

22. SIROLIMUS

23. TACROLIMUS

24. THEOPHYLLINE

25. TOBRAMYCIN

26. TOPIRIMATE

27. VALPROIC ACID

28. VANCOMYCIN

29. WARFARIN

B. Instrumentation Review: Operating characteristics and
features of high-, medium-, and low-volume/POC analyzers
manufactured by Abaxis, Abbott, Alere/Inverness,
Alfa Wassermann, AMS, Awareness Technologies, Beckman Coulter/Olympus,
Binding Site, bioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba,
Medica, Nova Biomedical, Ortho-Clinical Diagnostics, Polymedco, Randox,
Roche, Siemens, Tosoh, Vital Diagnostics and other suppliers
Table of Contents (Continued)
C. Major In Vitro Diagnostic Technologies
And Their Potential Applications

1. MONOCLONAL AND POLYCLONAL ANTIBODIES

2. IMMUNOASSAYS

a. Technological Principle
d. Chemiluminescence
c. Enzyme Immunoassays (EIA)
-Overview
-ELISA
-EMIT
-Electrochemical
d. Radioimmunoassays (RIA)
e. Immunoprecipitation
f. Affinity Chromatography

3. TANDEM MASS SPEC

4. IT AND AUTOMATION

5. DRY CHEMISTRY

6. BIOSENSORS

D. Market Size, Growth and Major Supplier Shares
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets

1. MARKETING APPROACHES

2. PRODUCT COMPLEXITY

3. CUSTOMER PREFERENCE

4. ESTABLISHED SUPPLIERS

5. EMERGING SUPPLIERS

6. MAJOR TYPES OF DISTRIBUTORS

7. MARKET SEGMENTATION

Table of Contents (Continued)
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Assessments
Abbott
Agilent Technologies
Beckman Coulter/Danaher
bioMerieux
Bio-Rad
DiaSorin
Eiken Chemical
Fujirebio
Grifols
IL/Werfen
Kyowa Medex
Ortho-Clinical Diagnostics
PerkinElmer
Quest Diagnostics
Roche
Siemens Healthineers
Sysmex
Thermo Fisher
Tosoh
Wako